ReviewInternational journal of molecular sciences2025
WW Domain-Containing E3 Ubiquitin Protein Ligase 1 (WWP1) as a Factor in Obesity-Related Metabolic Disorders: Emerging Molecular Mechanisms in Metabolic Tissues.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- WWP1 modulates metabolic adaptation in white adipose tissue but does not significantly modify caloric restriction-induced longevity in mice.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) is a member of the homologous to E6AP C-terminus-type E3 ubiquitin protein ligase family. Although WWP1 plays a role in several human diseases, including infectious diseases, neurological disorders, and cancers, there is emerging evidence that WWP1 is also associated with metabolic disorders. In this review, we discuss the regulation and molecular function of WWP1 and its contribution to obesity-related metabolic disorders, particularly in white adipose tissue and the liver. We highlight the need for further research to deepen our understanding of how WWP1 may be implicated in metabolic dysfunction and facilitate the development of novel therapeutic strategies that target WWP1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.